<DOC>
	<DOC>NCT02345044</DOC>
	<brief_summary>This study is a randomized, placebo-controlled, double-blind, multi-center study to evaluate efficacy and safety of different doses of CS-3150 compared to placebo in Japanese hypertensive subjects. Primary endpoint is change from baseline in sitting systolic and diastolic blood pressure.</brief_summary>
	<brief_title>A Study to Evaluate Efficacy and Safety of CS-3150 in Japanese Hypertensive Subjects</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Mineralocorticoid Receptor Antagonists</mesh_term>
	<mesh_term>Eplerenone</mesh_term>
	<criteria>Male and female subjects aged 20 years or older at informed consent Subjects with essential hypertension (Sitting SBP ≥ 140 mmHg and &lt; 180 mmHg, Sitting DBP ≥ 90 mmHg and &lt; 110 mmHg,and 24hhr blood pressure more than 130 mmHg in SBP and 80 mmHg in DBP) Secondary hypertension or malignant hypertension Diabetes mellitus with albuminuria Serum potassium level &lt; 3.5 or ≥ 5.1 mEq/L Reversed daynight life cycle including overnight workers eGFR &lt; 60 mL/min/1.73 m^2</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Essential hypertension</keyword>
	<keyword>mineralocorticoid receptor antagonist</keyword>
	<keyword>CS-3150</keyword>
	<keyword>Japanese</keyword>
</DOC>